Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 05/1/19 → 04/30/22 |
Funding
- Medeor Therapeutics Incorporated: $84,881.55
A Phase 3 Prospective, Randomized, Multicenter, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-Matched, Living Donor Kidney . . .
- Laftavi, Mark (PI)
Project: Research